Forum Financial Management LP Increases Stock Position in Johnson & Johnson $JNJ

Forum Financial Management LP increased its position in Johnson & Johnson (NYSE:JNJ) by 4.3% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 33,429 shares of the company’s stock after acquiring an additional 1,372 shares during the period. Forum Financial Management LP’s holdings in Johnson & Johnson were worth $5,106,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. GFG Capital LLC purchased a new position in Johnson & Johnson in the 2nd quarter worth approximately $35,000. Stone House Investment Management LLC purchased a new position in Johnson & Johnson in the 1st quarter worth approximately $47,000. 1248 Management LLC purchased a new position in Johnson & Johnson in the 1st quarter worth approximately $48,000. von Borstel & Associates Inc. purchased a new stake in Johnson & Johnson during the 1st quarter valued at $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in Johnson & Johnson during the 1st quarter valued at $52,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Down 0.3%

NYSE:JNJ opened at $192.31 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The firm has a market capitalization of $463.15 billion, a price-to-earnings ratio of 18.56, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. Johnson & Johnson has a one year low of $140.68 and a one year high of $194.48. The business has a fifty day moving average price of $181.99 and a 200-day moving average price of $165.84.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%. Sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Barclays boosted their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday, July 17th. Stifel Nicolaus boosted their target price on shares of Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a research note on Wednesday, October 15th. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Daiwa America upgraded shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Monday. Finally, Cowen reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 14th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $199.05.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.